Cargando…

Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis

BACKGROUND AND AIM: Vedolizumab is a humanized monoclonal antibody that selectively inhibits the migration of gut‐homing memory T cells into the intestinal submucosa by antagonizing the interaction of α(4)β(7) integrin with MAdCAM‐1. Vedolizumab is employed for ulcerative colitis with moderate to se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saito, Daisuke, Matsuura, Minoru, Ozaki, Ryo, Tokunaga, Sotaro, Minowa, Shintaro, Mitsui, Tatsuya, Miura, Miki, Sakuraba, Akihito, Hayashida, Mari, Miyoshi, Jun, Hisamatsu, Tadakazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Publishing Asia Pty Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454470/ https://www.ncbi.nlm.nih.gov/pubmed/34584975 http://dx.doi.org/10.1002/jgh3.12630

Ejemplares similares

Extent of disease affects the usefulness of fecal biomarkers in ulcerative colitis
por: Sakuraba, Akihito, et al.
Publicado: (2021)

Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis
por: Miyoshi, Jun, et al.
Publicado: (2021)

Evaluation of the drug-induced lymphocyte stimulation test for diagnosing mesalazine allergy
por: Saito, Daisuke, et al.
Publicado: (2018)

An HIV-infected Patient with Confirmed Overlapping Complications of Severe Amebic Colitis and CMV Enteritis
por: Morikubo, Hiromu, et al.
Publicado: (2018)

Endoscopic Treatment of Colo-Colonic Intussusception in a Patient with Peutz-Jeghers Syndrome
por: Fujima, Takeshi, et al.
Publicado: (2023)

Half-Elemental Diet Shifts the Human Intestinal Bacterial Compositions and Metabolites: A Pilot Study with Healthy Individuals
por: Miyoshi, Jun, et al.
Publicado: (2020)

Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis
por: Haga, Keiichi, et al.
Publicado: (2022)

Nutritional Status Indicators as a Predictor of Achieving Remission at Week 14 during Vedolizumab Therapy in Patients with Ulcerative Colitis: A Pilot Study
por: Sobolewska-Włodarczyk, Aleksandra, et al.
Publicado: (2023)

Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
por: Yagisawa, Keiji, et al.
Publicado: (2019)

Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
por: Yagisawa, Keiji, et al.
Publicado: (2020)

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
por: Feagan, Brian G, et al.
Publicado: (2019)

Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis
por: Naganuma, Makoto, et al.
Publicado: (2021)

Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis
por: Gonzalez-Vivo, Maria, et al.
Publicado: (2022)

Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis
por: Vermeire, Séverine, et al.
Publicado: (2020)

Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab
por: Scarozza, Patrizio, et al.
Publicado: (2020)

Treatment and outcomes: medical and surgical treatment for intestinal Behçet's disease
por: Hisamatsu, Tadakazu, et al.
Publicado: (2017)

Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2023)

Vedolizumab for induction and maintenance of remission in Crohn's disease
por: Hui, Samuel, et al.
Publicado: (2023)

Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis
por: Kobayashi, Taku, et al.
Publicado: (2019)

Combination of vedolizumab and immunomodulators in ulcerative colitis
por: Pinton, P
Publicado: (2021)

Cytomegalovirus Colitis in a Patient With Ulcerative Colitis on Vedolizumab Monotherapy
por: Meeralam, Yaser, et al.
Publicado: (2023)

5-Aminosalicylic acid alters the gut microbiota and altered microbiota transmitted vertically to offspring have protective effects against colitis
por: Wada, Haruka, et al.
Publicado: (2023)

Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis
por: Sandborn, William J, et al.
Publicado: (2019)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

A new endoscopic scoring system corresponding to histological healing using linked color imaging in ulcerative colitis: the SOUL study
por: Saito, Daisuke, et al.
Publicado: (2023)

Decreased Plasma Histidine Level Predicts Risk of Relapse in Patients with Ulcerative Colitis in Remission
por: Hisamatsu, Tadakazu, et al.
Publicado: (2015)

Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ study
por: Eder, Piotr, et al.
Publicado: (2023)

Patient considerations in the management of ulcerative colitis – role of vedolizumab
por: Kothari, Megha, et al.
Publicado: (2015)

Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis
por: Subhaharan, Deloshaan, et al.
Publicado: (2022)

Orbital Myositis in a Patient With Ileal Crohn's Disease in Remission on Vedolizumab
por: Sandhu, Sunny, et al.
Publicado: (2022)

Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling
por: Uda, Akihito, et al.
Publicado: (2020)

Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling
por: Uda, Akihito, et al.
Publicado: (2020)

Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission
por: Dubinsky, Marla C, et al.
Publicado: (2022)

5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis
por: Miyoshi, Jun, et al.
Publicado: (2018)

Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
por: Gilroy, Leah, et al.
Publicado: (2014)

New and emerging treatments for ulcerative colitis: a focus on vedolizumab
por: Gledhill, Tamsin, et al.
Publicado: (2013)

Identifying predictive signalling networks for Vedolizumab response in ulcerative colitis
por: Singh, Amrinder, et al.
Publicado: (2022)

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
por: Sablich, Renato, et al.
Publicado: (2023)

Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study
por: Eriksson, Carl, et al.
Publicado: (2021)

Selective biologics for ulcerative colitis and Crohn’s disease – clinical utility of vedolizumab
por: Petkau, Jill MV, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bf81v88os01tou11kfvim28l00